These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 25416783)

  • 1. Glycogen phosphomonoester distribution in mouse models of the progressive myoclonic epilepsy, Lafora disease.
    DePaoli-Roach AA; Contreras CJ; Segvich DM; Heiss C; Ishihara M; Azadi P; Roach PJ
    J Biol Chem; 2015 Jan; 290(2):841-50. PubMed ID: 25416783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Muscle glycogen remodeling and glycogen phosphate metabolism following exhaustive exercise of wild type and laforin knockout mice.
    Irimia JM; Tagliabracci VS; Meyer CM; Segvich DM; DePaoli-Roach AA; Roach PJ
    J Biol Chem; 2015 Sep; 290(37):22686-98. PubMed ID: 26216881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin.
    DePaoli-Roach AA; Tagliabracci VS; Segvich DM; Meyer CM; Irimia JM; Roach PJ
    J Biol Chem; 2010 Aug; 285(33):25372-81. PubMed ID: 20538597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased laforin and laforin binding to glycogen underlie Lafora body formation in malin-deficient Lafora disease.
    Tiberia E; Turnbull J; Wang T; Ruggieri A; Zhao XC; Pencea N; Israelian J; Wang Y; Ackerley CA; Wang P; Liu Y; Minassian BA
    J Biol Chem; 2012 Jul; 287(30):25650-9. PubMed ID: 22669944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormal metabolism of glycogen phosphate as a cause for Lafora disease.
    Tagliabracci VS; Girard JM; Segvich D; Meyer C; Turnbull J; Zhao X; Minassian BA; Depaoli-Roach AA; Roach PJ
    J Biol Chem; 2008 Dec; 283(49):33816-25. PubMed ID: 18852261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired malin expression and interaction with partner proteins in Lafora disease.
    Skurat AV; Segvich DM; Contreras CJ; Hu YC; Hurley TD; DePaoli-Roach AA; Roach PJ
    J Biol Chem; 2024 May; 300(5):107271. PubMed ID: 38588813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laforin is a glycogen phosphatase, deficiency of which leads to elevated phosphorylation of glycogen in vivo.
    Tagliabracci VS; Turnbull J; Wang W; Girard JM; Zhao X; Skurat AV; Delgado-Escueta AV; Minassian BA; Depaoli-Roach AA; Roach PJ
    Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19262-6. PubMed ID: 18040046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycogen synthase downregulation rescues the amylopectinosis of murine RBCK1 deficiency.
    Nitschke S; Sullivan MA; Mitra S; Marchioni CR; Lee JPY; Smith BH; Ahonen S; Wu J; Chown EE; Wang P; Petković S; Zhao X; DiGiovanni LF; Perri AM; Israelian L; Grossman TR; Kordasiewicz H; Vilaplana F; Iwai K; Nitschke F; Minassian BA
    Brain; 2022 Jul; 145(7):2361-2377. PubMed ID: 35084461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lafora disease offers a unique window into neuronal glycogen metabolism.
    Gentry MS; Guinovart JJ; Minassian BA; Roach PJ; Serratosa JM
    J Biol Chem; 2018 May; 293(19):7117-7125. PubMed ID: 29483193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The phosphatase activity of laforin is dispensable to rescue Epm2a-/- mice from Lafora disease.
    Gayarre J; Duran-Trío L; Criado Garcia O; Aguado C; Juana-López L; Crespo I; Knecht E; Bovolenta P; Rodríguez de Córdoba S
    Brain; 2014 Mar; 137(Pt 3):806-18. PubMed ID: 24430976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease.
    Nitschke F; Sullivan MA; Wang P; Zhao X; Chown EE; Perri AM; Israelian L; Juana-López L; Bovolenta P; Rodríguez de Córdoba S; Steup M; Minassian BA
    EMBO Mol Med; 2017 Jul; 9(7):906-917. PubMed ID: 28536304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Laforin is required for the functional activation of malin in endoplasmic reticulum stress resistance in neuronal cells.
    Zeng L; Wang Y; Baba O; Zheng P; Liu Y; Liu Y
    FEBS J; 2012 Jul; 279(14):2467-78. PubMed ID: 22578008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laforin and malin knockout mice have normal glucose disposal and insulin sensitivity.
    DePaoli-Roach AA; Segvich DM; Meyer CM; Rahimi Y; Worby CA; Gentry MS; Roach PJ
    Hum Mol Genet; 2012 Apr; 21(7):1604-10. PubMed ID: 22186021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of intracerebroventricular administration of alglucosidase alfa in two mouse models of Lafora disease: Relevance for clinical practice.
    Zafra-Puerta L; Colpaert M; Iglesias-Cabeza N; Burgos DF; Sánchez-Martín G; Gentry MS; Sánchez MP; Serratosa JM
    Epilepsy Res; 2024 Feb; 200():107317. PubMed ID: 38341935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are there errors in glycogen biosynthesis and is laforin a repair enzyme?
    Roach PJ
    FEBS Lett; 2011 Oct; 585(20):3216-8. PubMed ID: 21930129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased endoplasmic reticulum stress and decreased proteasomal function in lafora disease models lacking the phosphatase laforin.
    Vernia S; Rubio T; Heredia M; Rodríguez de Córdoba S; Sanz P
    PLoS One; 2009 Jun; 4(6):e5907. PubMed ID: 19529779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between glycogen accumulation and the laforin dual specificity phosphatase.
    Wang W; Parker GE; Skurat AV; Raben N; DePaoli-Roach AA; Roach PJ
    Biochem Biophys Res Commun; 2006 Nov; 350(3):588-92. PubMed ID: 17022935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lafora progressive myoclonus epilepsy: NHLRC1 mutations affect glycogen metabolism.
    Couarch P; Vernia S; Gourfinkel-An I; Lesca G; Gataullina S; Fedirko E; Trouillard O; Depienne C; Dulac O; Steschenko D; Leguern E; Sanz P; Baulac S
    J Mol Med (Berl); 2011 Sep; 89(9):915-25. PubMed ID: 21505799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycogen phosphorylation and Lafora disease.
    Roach PJ
    Mol Aspects Med; 2015 Dec; 46():78-84. PubMed ID: 26278984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene therapy for Lafora disease in the Epm2a
    Zafra-Puerta L; Iglesias-Cabeza N; Burgos DF; Sciaccaluga M; González-Fernández J; Bellingacci L; Canonichesi J; Sánchez-Martín G; Costa C; Sánchez MP; Serratosa JM
    Mol Ther; 2024 Jul; 32(7):2130-2149. PubMed ID: 38796707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.